Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 2—February 2007
Research

Neutralizing Antibodies after Infection with Dengue 1 Virus

Gustavo Kourí*Comments to Author , Mayling Alvarez*, Rosmari Rodriguez-Roche*, Lídice Bernardo*, Tibaire Montes†, Susana Vazquez*, Luis Morier*, Angel Alvarez*, Ernest A Gould‡, Maria G. Guzman*Comments to Author , and Scott B Halstead§
Author affiliations: *“Pedro Kourí” Tropical Medicine Institute, Havana, Cuba; †Instituto Medicina Tropical, Caracas, Venezuela; ‡Centre for Ecology and Hydrology, Oxford, United Kingdom; §Pediatric Dengue Vaccine Initiative, Bethesda, Maryland, USA;

Main Article

Table 2

Neutralization of dengue viruses by dengue virus 1–immune serum collected 4–8 years (group 1) and 20–22 years (group 2) after primary infection*

Serotype (strain)Group 1
Group 2
Positivity (%)GMTPositivity (%)GMT
DENV-1 (Jamaica/77)50 (100)9389 (100)140.6
DENV-2 (A15/81)6 (12)5.519 (21)6.5
DENV-2 (I348600)36 (72)†3040 (45)‡10.2
DENV-3 (116/00)4 (8)5.69 (10)5.9
DENV-4 (Dominica)1 (2)5.113 (15)6.2

*GMT, geometric mean titer; DENV, dengue virus.

†p<0.00001 compared with DENV-2 (A15/81), DENV-3, and DENV-4 viruses in group 1.

‡p<0.01–0.0001 compared with DENV-2 (A15/81), DENV-3, and DENV-4 viruses in group 2.

Main Article

Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external